CClinicalTrials.gg
Not yet recruitingNCT05782738T-REXUpdated Apr 19, 2023

Reverse T-stenting and Minimal Protrusion With External Minicrush for Treatment of Complex Coronary Bifurcation

An interventional study of Percutaneous Coronary Intervention in Coronary Artery Disease, Coronary Stenosis and Coronary Disease, sponsored by San Luigi Gonzaga Hospital. Not yet recruiting at 5 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-19.

Sponsored by San Luigi Gonzaga Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
361
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The Reverse T-stenting And Minimal Protrusion (Reverse TAP) is an up-front 2-stent technique that treats complex coronary bifurcation. Compared to crush techniques, it does not require crushing of the side branch stent but only minimal protrusion of the side branch stent before main vessel stenting. Nowadays, no studies compare the Reverse-TAP and the External Minicrush in treating complex coronary bifurcation, so eventually, procedural, clinical and safety differences remain unknown.

Read the detailed description

According to DEFINITION criteria, PCI of the complex coronary bifurcation with up-front two stent techniques is associated with lower target vessel revascularisation (TVR) than Provisional Stenting. The Double-Kissing Crush stenting (DK-Crush) has been tested with the Culotte and the Classic Crush techniques in the unprotected left main disease (ULMD) and in no-ULMD setting, respectively, showing better clinical outcomes. However, due to its technical complexity and simultaneous improvement of the Classic Crush technique in the External Minicrush, the latter has become the most used technique in the clinical practice in treating complex coronary bifurcation. The DK-Crush technique has never been tested with the External Minicrush, leaving the operators to choose one or the other according to their experience and preferences. The Reverse T-stenting, And Minimal Protrusion (Reverse TAP) is an up-front 2-stent technique that treats complex coronary bifurcation. Compared to crush techniques, it does not require crushing of the side branch stent but only minimal protrusion of the side branch stent before main vessel stenting. Nowadays, studies need to compare the Reverse-TAP and the External Minicrush in treating complex coronary bifurcation, so eventually, procedural, clinical and safety differences remain unknown.

02

Conditions studied

  • Coronary Artery Disease
  • Coronary Stenosis
  • Coronary Disease

Keywords

  • Reverse TAP
  • External Minicrush
  • Coronary bifurcation lesion
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients >18 years old;
  • Patients with an indication of PCI, including Chronic Coronary syndrome (CCS) and Acute Coronary Syndrome (ACS), according to current guidelines recommendations; According to Medina and Definition criteria, patients with at least true and complex coronary lesions involved in coronary bifurcation.

Exclusion criteria

Exclusion Criteria:

  • Patients that refused informed consent;
  • Patients without valid vascular access that could make unsafe PCI;
  • Patients with an expected life of less than one year;
  • Patients with scheduled major surgery that required prolonged DAPT interruption;
  • Pregnant patients;
  • Patients with DAPT contraindications.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
361 participants (estimated)

Study arms

  • Active comparator
    Reverse TAP

    Procedure: Percutaneous Coronary Intervention

  • Active comparator
    External Minicrush

    Procedure: Percutaneous Coronary Intervention

Interventions

  • ProcedurePercutaneous Coronary Intervention

    Use dedicated two stents technique for treatment of coronary bifurcation stenosis

05

What researchers measure

Primary outcomes

  1. Target Lesion Failure (TLF) (Composite of all causes of death, non-fatal TVMI, ischemia-driven target lesion revascularisation (TLR) + Definite or probable ST+ ISR >50% at planned coronary angiography or Coro-TC.

    The investigators check eventually differences in technical and clinical performance between the two techniques through coronary angiography or Coro-TC (centre preferences).

    Time frame: 12-moths

Secondary outcomes

  1. Cardiac death + TVMI + ST

    The investigators check mid-term cardiovascular clinical performance between the two techniques.

    Time frame: 5-years

  2. Cardiac death + TVMI + ST +TLR

    The investigators check mid-term cardiovascular clinical performance between the two techniques, including any revascularization of the target lesion site.

    Time frame: 5-years

Other outcomes

  1. Acute closure of the side branch and periprocedural-MI.

    The investigators check safety of procedural profile between two techniques.

    Time frame: Periprocedural

  2. Intraprocedural ST and periprocedural-MI

    The investigators check safety of procedural profile between two techniques.

    Time frame: Periprocedural

  3. Major bleeding (BARC 3 and 5)

    The investigators check safety of hemorrhagic profile between two techniques in consideration of prolonged DAPT.

    Time frame: 5-years

  4. Technical success

    Defined as TIMI flow 3 and \< 30% residual stenosis after PCI on target vessel

    Time frame: Procedural

  5. Procedural success

    Defined as technical success with no in-hospital major adverse

    Time frame: Periprocedural

  6. Cross-over between groups

    Possibility to switching between two techniques for technical reasons

    Time frame: Periprocedural

  7. Timing of rewiring

    Measure of the time spending in a crucial phase of the two techniques

    Time frame: Periprocedural

  8. Number of guide wire used

    Number of coronary guidewires to perform the assigned technique.

    Time frame: Periprocedural

  9. Amount of contrast medium used

    Total contrast medium used to perform the PCI with the technique assigned

    Time frame: Periprocedural

  10. Procedural time

    Total time used to perform the PCI

    Time frame: Periprocedural

  11. Fluoroscopic time

    Total fluoroscopic time spending to perform the PCI

    Time frame: Periprocedural

  12. X-rays exposition

    Total operators x-rays exposition during the PCI

    Time frame: Periprocedural

06

Study locations

5 sites
  • Ciriè Hospital
    Ciriè, Tori O 10073, Italy
  • Ospedale Santa Croce
    Moncalieri, Torino 10024, Italy
  • Azienda ospedaliera Santi Antonio e Biagio e Cesare Arrigo
    Alessandria, 15121, Italy
  • L'Azienda Ospedaliera (AO) S. Croce e Carle
    Cuneo, 12100, Italy
  • Interventional Unit, San Luigi Gonzaga University Hospital, Orbassano, and Rivoli Hospital, Turin, Italy
    Turin, 10100, Italy
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT05782738
Lead sponsor
San Luigi Gonzaga Hospital
Responsible party
Enrico Cerrato (Interventional Cardiology, San Luigi Gonzaga Hospital) — Principal investigator
First posted
Mar 24, 2023
Start date
Jun 1, 2023 (estimated)
Primary completion
Jun 1, 2026 (estimated)
Completion
Jun 1, 2029 (estimated)
Last update
Apr 19, 2023

Study contacts

Giulio Piedimonte, MD
Contact
giulio.piedimonte@gmail.com
+393201764900
Enrico Cerrato, MD, phD
Contact
enrico.cerrato@gmail.com
Giulio Piedimonte, MD
principal investigator · Ospedale degli Infermi di Rivoli (TO)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion